Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG TEMPO PEN versus NOVOLOG PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG TEMPO PEN versus NOVOLOG PENFILL.
HUMALOG TEMPO PEN vs NOVOLOG PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase and downstream signaling pathways.
Insulin aspart is a rapid-acting recombinant human insulin analog. It lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, promoting glucose uptake, and inhibiting hepatic glucose production via glycogenolysis and gluconeogenesis.
Subcutaneously, 0.2-0.5 units/kg within 15 minutes before or after a meal. Total daily dose is 0.5-1.0 units/kg.
Subcutaneous injection: 0.5-1 unit/kg/day divided into multiple doses (e.g., basal-bolus regimen). Individualized based on glucose monitoring.
None Documented
None Documented
1.0 hour (terminal elimination half-life); reflects rapid clearance of insulin lispro from circulation.
~5-7 minutes (free insulin aspart); clinical effect duration correlates with SC absorption half-life ~1-2 hours
Renal: 100% of absorbed dose is eliminated via degradation, primarily in the liver and kidneys; no significant biliary/fecal excretion.
Renal: 60-80% as metabolites; unchanged drug excreted minimally. Fecal: <10%
Category C
Category C
Insulin Analog
Insulin Analog